Maha Othman

@queensu.ca

Professor
Queen University



              

https://researchid.co/mothman
48

Scopus Publications

1680

Scholar Citations

13

Scholar h-index

27

Scholar i10-index

Scopus Publications

  • The incidence of venous thromboembolism by type of solid cancer worldwide: A systematic review
    Jordan Harry, Regan Bucciol, Deirdre Finnigan, Hussein Hashem, Ahmad Araki, and Maha Othman
    Elsevier BV

  • The role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as venous thromboembolism predictors in breast cancer patients pre- and post-therapy
    Alyssa Qian, Armita Zandi, Regan Bucciol, and Maha Othman
    Ovid Technologies (Wolters Kluwer Health)
    Objectives Breast cancer (BC) accounts for 12.3% of all cancer-associated venous thromboembolism (VTE). Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are recognized inflammatory biomarkers but have not been incorporated into thrombosis risk stratification models. We evaluated NLR and PLR as predictive biomarkers for VTE in BC patients to determine their optimal predictive cutoffs and net predictive value before and after treatment. Methods We conducted a prospective pilot study that involved 56 women with BC, recruited prior to treatment (chemotherapy and immunotherapy) initiation with at least 6-month monitoring for VTE. NLR and PLR were assessed pre and posttreatment. Results Five patients (8.9%) developed VTE. NLR and PLR increased significantly posttreatment (P = 0.001). Post, not pretreatment, NLR (P = 0.029) and PLR (P = 0.033) were significantly associated with VTE occurrence. Receiver Operating curve analysis indicated enhanced predictive capacity for VTE postimmunotherapy. Optimal posttreatment cutoffs were 3.6 for NLR and 280 for PLR, aligning with existing literature, with slightly elevated NLR. Conclusions Posttreatment NLR and PLR have higher predictability for VTE in patients receiving immunotherapy compared to chemotherapy. NLR outperforms PLR, particularly postimmunotherapy. This data holds promise for thrombosis risk stratification in the context of immunotherapy but requires evaluation in larger studies.

  • Red blood cell changes due to cancer and cancer treatments: A narrative review
    Deirdre Finnigan, Omar I. Hajjaj, and Maha Othman
    Ovid Technologies (Wolters Kluwer Health)
    Purpose of review To date, there is relatively limited research investigating changes in red blood cells (RBCs), particularly qualitative changes, in cancer patients and cancer patients receiving treatment. These changes may be important in better understanding cancer-associated anemia, which is the most prevalent hematological disorder in cancer patients with wide-ranging implications on patient care and quality of life. This review aims to summarize available evidence regarding qualitative and quantitative changes in RBCs in individuals with cancer prior to treatment and in patients undergoing treatment. Recent findings The most commonly reported changes in RBCs in cancer patients were increased mean corpuscular volume (MCV) and decreased hemoglobin, RBC count, and hematocrit. There were increased lipid peroxidation products and decreased antioxidants. There were increased polyunsaturated fatty acids (PUFAs) and decreased monounsaturated fatty acids (MUFAs) and saturated fatty acids (FAs). Additionally, RBC shape alterations with various atypical morphologies, membrane structure abnormalities, and impaired fluidity were also reported. These and various other reported findings are discussed in depth. Summary There are several reported quantitative and qualitative RBC changes in individuals with cancer, with some studies exhibiting conflicting results. Further research is needed to solidify the data and to better understand hematological-associated comorbidities in those patients.

  • Characterizing coagulation responses in humans and nonhuman primates following kidney xenotransplantation—A narrative review
    Ali Zidan, Adham H. El‐Sherbini, Abdelrahman Noureldin, David K. C. Cooper, and Maha Othman
    Wiley
    AbstractThe recent report of the first pig kidney transplant in a living human brings hope to thousands of people with end‐stage kidney failure. The scientific community views this early success with caution as kidney xenotransplantation exhibits many challenges and barriers. One of these is coagulation dysregulation. This includes (i) pig von Willebrand Factor (vWF) interaction with human platelets, which can induce abnormal clotting responses, heightening the risk of graft failure, (ii) the inefficiency of pig thrombomodulin in activating human protein C, which emphasizes the species‐specific variations that aggravate coagulation challenges, and (iii) the development of thrombotic microangiopathy in the pig grafts and the occurrence of systemic consumptive coagulopathy in the recipients. Indeed, coagulation dysregulation largely results from differences in endothelial cell response and incompatibilities between pig and human coagulation–anticoagulation pathways. These barriers can be resolved by modifications to pig vWF and the expression of human thrombomodulin and endothelial protein C receptors in pig cells, serving as strategic interventions to align the coagulation systems of the two species more closely. These coagulation challenges have clinical implications in how they affect graft survival and patient outcome. Genetic engineering of the organ‐source pig and the administration of various drugs have assisted in correcting this coagulation dysregulation. Hence, comprehending and controlling coagulation dysregulation is crucial for progress in xenotransplantation as a viable option for treating patients with terminal kidney disease.

  • Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening
    Mazen Assar, Henning Nilius, Natalie Kearn, Wilma Hopman, Michael Nagler, and Maha Othman
    Wiley
    ABSTRACTIntroductionThrombophilia, a blood coagulation disorder, poses risks of venous thromboembolism (VTE). Coagulation assays may not be sufficient to assess VTE risk and global assays such as Rotational Thromboelastometry (ROTEM) may add valuable information. We investigated ROTEM's capacity to detect hypercoagulability in patients undergoing thrombophilia screening, its potential impact on patient outcomes, and limitations.MethodsComprehensive clinical, laboratory, genetic tests, and ROTEM (EXTEM and INTEM) were conducted for 356 patients referred for thrombophilia screening at an academic hospital outpatient unit. Hypercoagulability was identified as a shorter clot formation time (CFT), larger alpha angle (AA), and greater maximum clot firmness (MCF), and was compared in patients with and without VTE. Statistically this was analyzed using Mann–Whitney U and Chi‐square tests with p < 0.05 considered significant.ResultsAmong 356 patients, 64.6% had previous VTE, with 76.9% experiencing one event, 14.3% recurrent (35.6% unprovoked, 64.4% provoked). 22.5% of patients were on anticoagulation. Those with VTE history exhibited significant alterations in EXTEM and INTEM parameters compared to those without (p < 0.001), showing decreased CFT and increased AA and MCF. However, receiver operating characteristic curves for these variables indicated that none were able to discriminate between those individuals with and without thromboembolic complications.ConclusionROTEM does not appear to be a strong discriminatory test. However, it can detect hypercoagulopathy in patients referred for thrombophilia screening. Abnormal ROTEM may indicate a higher risk for recurrence. However, this can only be determined in prospective cohort studies.

  • Global prevalence of platelet-type von Willebrand disease
    Omid Seidizadeh, Andrea Cairo, Maha Othman, and Flora Peyvandi
    Elsevier BV

  • Deranged Balance of Hemostasis and Fibrinolysis in Disseminated Intravascular Coagulation: Assessment and Relevance in Different Clinical Settings
    Ecaterina Scarlatescu, Toshiaki Iba, Cheryl L. Maier, Hunter Moore, Maha Othman, Jean Marie Connors, and Jerrold H. Levy
    Ovid Technologies (Wolters Kluwer Health)
    The disruption of hemostasis/fibrinolysis balance leads to disseminated intravascular coagulation, manifested clinically by bleeding or thrombosis, and multiorgan failure. This study reviews hemostatic assessment and therapeutic strategies that restore this balance in critically ill patients.

  • Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
    Ross I. Baker, Philip Choi, Nicola Curry, Johanna Gebhart, Keith Gomez, Yvonne Henskens, Floor Heubel-Moenen, Paula James, Rezan Abdul Kadir, Peter Kouides,et al.
    Elsevier BV

  • Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database
    Sydney Penfound, Alexandra Lukey, Jessica Hodgson, Wilma M. Hopman, Gillian E. Hanley, and Maha Othman
    Elsevier BV

  • Management of Venous and Arterial Thrombosis
    Lucia Stančiaková, Maha Othman, and Peter Kubisz
    MDPI AG
    A thrombus is a hemostatic plug localized in a blood vessel [...]

  • Machine Learning as a Diagnostic and Prognostic Tool for Predicting Thrombosis in Cancer Patients: A Systematic Review
    Adham H. El-Sherbini, Stefania Coroneos, Ali Zidan, and Maha Othman
    Georg Thieme Verlag KG
    AbstractKhorana score (KS) is an established risk assessment model for predicting cancer-associated thrombosis. However, it ignores several risk factors and has poor predictability in some cancer types. Machine learning (ML) is a novel technique used for the diagnosis and prognosis of several diseases, including cancer-associated thrombosis, when trained on specific diagnostic modalities. Consolidating the literature on the use of ML for the prediction of cancer-associated thrombosis is necessary to understand its diagnostic and prognostic abilities relative to KS. This systematic review aims to evaluate the current use and performance of ML algorithms to predict thrombosis in cancer patients. This study was conducted per Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Databases Medline, EMBASE, Cochrane, and ClinicalTrials.gov, were searched from inception to September 15, 2023, for studies evaluating the use of ML models for the prediction of thrombosis in cancer patients. Search terms “machine learning,” “artificial intelligence,” “thrombosis,” and “cancer” were used. Studies that examined adult cancer patients using any ML model were included. Two independent reviewers conducted study selection and data extraction. Three hundred citations were screened, of which 29 studies underwent a full-text review, and ultimately, 8 studies with 22,893 patients were included. Sample sizes ranged from 348 to 16,407 patients. Thrombosis was characterized as venous thromboembolism (n = 6) or peripherally inserted central catheter thrombosis (n = 2). The types of cancer included breast, gastric, colorectal, bladder, lung, esophageal, pancreatic, biliary, prostate, ovarian, genitourinary, head–neck, and sarcoma. All studies reported outcomes on the ML's predictive capacity. The extreme gradient boosting appears to be the best-performing model, and several models outperform KS in their respective datasets.

  • Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy
    Yousra Tera, Yoon Jin Suh, Karina Fainchtein, Anita Agrawal, Mihaela Mates, and Maha Othman
    Wiley
    AbstractVenous thromboembolism (VTE) is a common occurrence in cancer and chemotherapy increases thrombosis risk. Current risk assessment models such as the Khorana score (KS) and its modifications have limitations in female cancers. We assessed the coagulation profile of a group of women cancer patients under chemotherapy using thromboelastography (TEG) to determine if this can inform VTE risk assessment. Cancer patients who planned to receive chemotherapy were recruited. Baseline demographics, cancer data, BMI, Khorana Score (KS), and VTE risk factors were recorded and patients were followed for 6 months, for any thrombotic events. A total of 36 patients aged 35–85 (18 breast, 11 endometrial, 7 ovarian cancer) were evaluated. Hypercoagulability was detected in 63% of patients post‐chemo cycle 1 and 75% post‐cycle 2, with a significant increase in MA (maximum amplitude) and CI (clotting index), reduction in R (reaction time), K (clot kinetics), and LY30 (lysis time after 30 min of MA). KS showed only 7% of patients were high risk, 23% were low, and 70% were intermediate risk. MA and CI significantly increased in patients with intermediate and high‐risk KS when compared with the low‐risk patients and MA was positively correlated with KS. Five patients developed actual VTE; 100% of the tested ones were hypercoagulable either post‐cycle 1 or 2 and 80% were KS intermediate risk. TEG is a hypercoagulability marker and TEG‐MA and CI can potentially assess VTE risk. Larger studies are needed to assess the utility of TEG as an adjuvant to KS to better predict VTE in specific female cancers.

  • ABO Blood Group and the Risk of Thrombosis in Cancer Patients: A Mini-Review
    Salah Elsherif, Ali Zidan, Olivia Saville, and Maha Othman
    Georg Thieme Verlag KG
    AbstractCancer-associated thrombosis (CT), especially venous thromboembolism (VTE), is a common occurrence with several factors contributing to a wide diversity in thrombosis risk. The association between ABO blood groups and the risk for CT has been examined in various studies, with non-O blood type associated with an increased thrombosis risk; however, these studies have reported varying results with recognized limitations. ABO blood groups are known to be implicated in hemostasis, in an association mediated through von Willebrand factor (VWF). In this narrative review, we aim to summarize the current knowledge surrounding the role of ABO blood groups in VTE, with a particular focus on the role of VWF and other contributing risk factors on VTE occurrence. We found evidence from literature for the impact of ABO blood groups in determining the risk of VTE in healthy populations, with a limited number of studies examining this effect in cancer patients. Additionally, research on the impact of ABO on different cancer types lacks rigor, particularly in regard to other risk factors. Overall, most studies showed strong association of increased risk of VTE amongst cancer patients with non-O blood groups and increased VWF levels. This association was weaker in a few studies. Further research is needed before a solid conclusion can be made about the ABO or ABO-VWF-mediated hypercoagulability and VTE risk in various cancers. These studies will help determine if ABO typing can be an added biomarker to improve VTE risk assessment models in cancer patients.

  • Report of the ISTH registry on pregnancy and COVID-19-associated coagulopathy (COV-PREG-COAG)
    Sajida Kazi, Maha Othman, Rasha Khoury, Peter S Bernstein, Jecko Thachil, Etienne Ciantar, Laura Ferrara, Manju Netto, Rezan Abdul-Kadir, and A Kinga Malinowski
    SAGE Publications
    Background Concerns about COVID-19-associated coagulopathy (CAC) in pregnant individuals were raised in early pandemic. Methods An ISTH-sponsored COVID-19 coagulopathy in pregnancy (COV-PREG-COAG) international registry was developed to describe incidence of coagulopathy, VTE, and anticoagulation in this group. Results All pregnant patients with COVID-19 from participating centers were entered, providing 430 pregnancies for the first pandemic wave. Isolated abnormal coagulation parameters were seen in 20%; more often with moderate/severe disease than asymptomatic/mild disease (49% vs 15%; p < 0.0001). No one met the ISTH criteria for disseminated intravascular coagulopathy (DIC), though 5/21 (24%) met the pregnancy DIC score. There was no difference in antepartum hemorrhage (APH) with asymptomatic/mild disease versus moderate/severe disease (3.4% vs 7.7%; p = 0.135). More individuals with moderate/severe disease experienced postpartum hemorrhage (PPH) (22.4% vs 9.3%; p = 0.006). There were no arterial thrombotic events. Only one COVID-associated venous thromboembolism (VTE) was reported. Conclusions Low rates of coagulopathy, bleeding, and thrombosis were observed among pregnant people in the first pandemic wave.

  • Precision Medicine in Rare Bleeding Disorders
    Akbar Dorgalaleh and Maha Othman
    Georg Thieme Verlag KG

  • Platelet-Type von Willebrand Disease: Complex Pathophysiology and Insights on Novel Therapeutic and Diagnostic Strategies
    Anne Fu, Thomas D.D. Kazmirchuk, Calvin Bradbury-Jost, Ashkan Golshani, and Maha Othman
    Georg Thieme Verlag KG
    Abstractvon Willebrand disease (VWD) is the most common well-studied genetic bleeding disorder worldwide. Much less is known about platelet-type VWD (PT-VWD), a rare platelet function defect, and a “nonidentical” twin bleeding phenotype to type 2B VWD (2B-VWD). Rather than a defect in the von Willebrand factor (VWF) gene, PT-VWD is caused by a platelet GP1BA mutation leading to a hyperaffinity of the glycoprotein Ibα (GPIbα) platelet surface receptor for VWF, and thus increased platelet clearing and high-molecular-weight VWF multimer elimination. Nine GP1BA gene mutations are known. It is historically believed that this enhanced binding was enabled by the β-switch region of GPIbα adopting an extended β-hairpin form. Recent evidence suggests the pathological conformation that destabilizes the compact triangular form of the R-loop—the GPIbα protein's region for VWF binding. PT-VWD is often misdiagnosed as 2B-VWD, even the though distinction between the two is crucial for proper treatment, as the former requires platelet transfusions, while the latter requires VWF/FVIII concentrate administration. Nevertheless, these PT-VWD treatments remain unsatisfactory, owing to their high cost, low availability, risk of alloimmunity, and the need to carefully balance platelet administration. Antibodies such as 6B4 remain undependable as an alternative therapy due to their questionable efficacy and high costs for this purpose. On the other hand, synthetic peptide therapeutics developed with In-Silico Protein Synthesizer to disrupt the association between GPIbα and VWF show preliminary promise as a therapy based on in vitro experiments. Such peptides could serve as an effective diagnostic technology for discriminating between 2B-VWD and PT-VWD, or potentially all forms of VWD, based on their high specificity. This field is rapidly growing and the current review sheds light on the complex pathology and some novel potential therapeutic and diagnostic strategies.

  • Hematologic characteristics and coagulopathy in pregnancy with COVID-19 succeeding the first wave: a multicenter retrospective cross-sectional study
    Maha Othman, Georgiana Nemeti, Marissa Solow, Gheorghe Cruciat, Daniel Muresan, Mariam Suzana Chaikh Sulaiman, Shivani Thaker, Rezan Abdul-Kadir, and A. Kinga Malinowski
    Elsevier BV

  • Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models
    Hanaa Ali EL-Sayed, Maha Othman, Hanan Azzam, Regan Bucciol, Mohamed Awad Ebrahim, Mohammed Ahmed Mohammed Abdallah EL-Agdar, Yousra Tera, Doaa H. Sakr, Hayam Rashad Ghoneim, and Tarek El-Sayed Selim
    Springer Science and Business Media LLC

  • Tissue factor positive microparticles as a biomarker for increased risk of breast cancer-associated thrombosis: a mini review
    Regan Bucciol and Maha Othman
    Ovid Technologies (Wolters Kluwer Health)
    Purpose of review Cancer-associated thrombosis (CAT), such as venous thromboembolism (VTE), is a frequent complication in cancer patients, resulting in poor prognosis. Breast cancer is not highly thrombogenic but is highly prevalent, resulting in increased VTE cases. Many cancers express tissue factor (TF), a glycoprotein that triggers coagulation. The cancer cells were shown to express and release substantial amounts of TF-positive microparticles (MPTF), associated with a prothrombotic state. This narrative review evaluated the current use of the procoagulant MPTF as a biomarker for thrombosis risk in breast cancer. Recent findings Tumors of epithelial origin with elevated TF expression have been associated with increased VTE incidence. Thus, studies have affirmed the use of MPTF biomarkers for VTE risk in many cancers. Patients with metastatic breast cancer and CAT were found to exhibit elevated procoagulant microparticles in vitro, due to TF expression. The silencing of TF was associated with decreased microparticle release in breast carcinoma cell lines, associated with decreased coagulation. Summary CAT is a multifactorial condition, with several various underlying diseases. It is proposed that MPTF may be an effective biomarker for thrombosis risk in breast cancer patients but requires a more systemic evaluation utilizing standardized quantification methods.

  • Evaluating the hemostatic effects of tranexamic acid in women with pre-eclampsia
    Helen C. Okoye, Maha Othman, Theresa U. Nwagha, Daniel N. Onwusulu, Robinson C. Onoh, and Chibuike O. Chigbu
    Wiley
    OBJECTIVE To evaluate the hemostatic effects of tranexamic acid (TXA) ex vivo in women with pre-eclampsia. METHODS This was an ex vivo study involving 45 normal pregnant women and 45 women with pre-eclampsia (nine with mild and 36 with severe features) matched for age, gestational age, and body mass index. Blood samples were collected and divided into two parts. The first served as the pre-TXA sample, while the second was spiked with TXA and served as the post-TXA sample. Plasma levels of D-dimer and plasmin-antiplasmin complex (PAP) were determined using enzyme-linked immunosorbent assay. RESULTS The mean D-dimer and PAP values in the pre-TXA samples differed significantly between groups. Following spiking with TXA, the mean D-dimer and PAP levels did not differ significantly in the pre-TXA and post-TXA samples (P = 0.560 and P = 0.500, respectively) in the pre-eclampsia cohort. In normal pregnancy, the mean D-dimer and PAP levels in the post-TXA samples did not differ significantly (P = 0.070 and P = 0.050, respectively) from the pre-TXA samples following TXA spiking. CONCLUSION TXA did not significantly affect D-dimer and PAP levels in pre-eclampsia, suggesting that TXA may not increase the thrombotic risks in patients with pre-eclampsia.


  • The ART of Thromboprophylaxis in the Prevention of Gestational Venous Thromboembolism
    Elvira Grandone, Doris Barcellona, Mariano Intrieri, Giovanni Tiscia, Luigi Nappi, and Maha Othman
    Georg Thieme Verlag KG
    AbstractAssisted reproductive techniques (ART) allow infertile couples to conceive. Use of hormones to obtain a controlled ovarian stimulation and an adequate growth of the endometrium preparatory for embryo implantation are not riskless. Among others, thrombotic events can occur during the ovulation induction or pregnancy following ART. As the number of women approaching ART to conceive is steadily increasing, the issue of thrombotic risk in this setting is relevant. Data on the weight of each risk factor and on potential benefit of thromboprophylaxis are largely lacking. In this review, we discuss risk of venous thromboembolism during pregnancy following ART, with a focus on general (i.e.: age, body mass index, thrombophilia, bed rest, transfusions) and ART-specific (i.e., polycystic ovarian syndrome, ovarian hyperstimulation syndrome) risk factors. We also attempt to provide some suggestions to guide clinical practice, based on available data and studies performed outside ART.




RECENT SCHOLAR PUBLICATIONS

  • The incidence of venous thromboembolism by type of solid cancer worldwide: A systematic review
    J Harry, R Bucciol, D Finnigan, H Hashem, A Araki, M Othman
    Cancer Epidemiology 95, 102764 2025

  • The role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as venous thromboembolism predictors in breast cancer patients pre-and post-therapy
    A Qian, A Zandi, R Bucciol, M Othman
    Blood Coagulation & Fibrinolysis 36 (2), 62-67 2025

  • Red blood cell changes due to cancer and cancer treatments: a narrative review
    D Finnigan, OI Hajjaj, M Othman
    Current Opinion in Hematology 32 (2), 93-103 2025

  • Optimal Cutoff for Neutrophil-to-Lymphocyte Ratio as a Tool for Pre-Chemotherapy Prognosis Stratification of Breast Cancer Patients
    A Zandi, A Qian, R Bucciol, M Othman
     2025

  • Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening
    M Assar, H Nilius, N Kearn, W Hopman, M Nagler, M Othman
    International Journal of Laboratory Hematology 2025

  • Characterizing coagulation responses in humans and nonhuman primates following kidney xenotransplantation—A narrative review
    A Zidan, AH El‐Sherbini, A Noureldin, DKC Cooper, M Othman
    American Journal of Hematology 100 (2), 285-295 2025

  • Global prevalence of platelet-type von Willebrand disease
    O Seidizadeh, A Cairo, M Othman, F Peyvandi
    Research and Practice in Thrombosis and Haemostasis 9 (1), 102682 2025

  • THE ROLE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN ASSESSING DISEASE PROGRESSION AND OUTCOMES IN BREAST CANCER
    A Qian, A Zandi, M Othman
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 46, 82-83 2024

  • ABO BLOOD GROUPS, HYPERCOAGULABILITY AND THROMBOSIS RISK IN WOMEN WITH CANCER UNDERGOING CHEMOTHERAPY
    Y Tera, S Elsherif, A Kini, R Bucciol, H Parente, A Agrawal, M Mates, ...
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 46, 102-102 2024

  • MACHINE LEARNING FOR PREDICTING THROMBOSIS IN CANCER PATIENTS: A SYSTEMATIC REVIEW
    A El-Sherbini, S Coroneos, A Zidan, M Othman
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 46, 34-34 2024

  • EVALUATING PREDICTIVE TOOLS FOR THROMBOSIS RISK ASSESSMENT IN BREAST CANCER-UNMET NEED
    R Bucciol, Y Tera, C Bunker, A Kini, M Mates, M Othman
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 46, 19-19 2024

  • Red Cell Distribution Width and the Early Detection of Ovarian Cancer
    Y Abossi, M Othman
    Qapsule: Queen's Undergraduate Health Sciences Journal 1 (2) 2024

  • 2024 Eberhard F. Mammen Award Announcements: part I—most popular articles
    EJ Favaloro
    Seminars in thrombosis and hemostasis 50 (07), 919-932 2024

  • Deranged balance of hemostasis and fibrinolysis in disseminated intravascular coagulation: assessment and relevance in different clinical settings
    E Scarlatescu, T Iba, CL Maier, H Moore, M Othman, JM Connors, ...
    Anesthesiology 141 (3), 570-583 2024

  • Machine learning as a diagnostic and prognostic tool for predicting thrombosis in cancer patients: a systematic review
    AH El-Sherbini, S Coroneos, A Zidan, M Othman
    Seminars in Thrombosis and Hemostasis 50 (06), 809-816 2024

  • Platelet-type von Willebrand disease: complex pathophysiology and insights on novel therapeutic and diagnostic strategies
    A Fu, TDD Kazmirchuk, C Bradbury-Jost, A Golshani, M Othman
    Seminars in Thrombosis and Hemostasis 2024

  • Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
    RI Baker, P Choi, N Curry, J Gebhart, K Gomez, Y Henskens, ...
    Journal of thrombosis and haemostasis 22 (7), 2059-2070 2024

  • Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer-data from a large Canadian database
    S Penfound, A Lukey, J Hodgson, WM Hopman, GE Hanley, M Othman
    Gynecologic Oncology 185, 116-120 2024

  • Management of Venous and Arterial Thrombosis
    L Stančiakov, M Othman, P Kubisz
    Journal of Clinical Medicine 13 (10), 2744 2024

  • Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy
    Y Tera, YJ Suh, K Fainchtein, A Agrawal, M Mates, M Othman
    American Journal of Hematology 99, S19-S27 2024

MOST CITED SCHOLAR PUBLICATIONS

  • The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study
    PD James, C Notley, C Hegadorn, J Leggo, A Tuttle, S Tinlin, C Brown, ...
    Blood 109 (1), 145-154 2007
    Citations: 422

  • Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance
    M Othman, A Labelle, I Mazzetti, HS Elbatarny, D Lillicrap
    Blood 109 (7), 2832-2839 2007
    Citations: 284

  • A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders
    I Simeoni, JC Stephens, F Hu, SVV Deevi, K Megy, TK Bariana, ...
    Blood, The Journal of the American Society of Hematology 127 (23), 2791-2803 2016
    Citations: 196

  • Standardization of thromboelastography: a report from the TEG‐ROTEM working group
    M Chitlur, B Sorensen, GE Rivard, G Young, J Ingerslev, M Othman, ...
    Haemophilia 17 (3), 532-537 2011
    Citations: 185

  • Association of SARS-CoV-2 infection during pregnancy with maternal and perinatal outcomes
    E McClymont, AY Albert, GD Alton, I Boucoiran, E Castillo, DB Fell, ...
    Jama 327 (20), 1983-1991 2022
    Citations: 180

  • Spontaneous pregnancy loss mediated by abnormal maternal inflammation in rats is linked to deficient uteroplacental perfusion
    SJ Renaud, T Cotechini, JS Quirt, SK Macdonald-Goodfellow, M Othman, ...
    The Journal of Immunology 186 (3), 1799-1808 2011
    Citations: 152

  • A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH
    KPM van Galen, R d’Oiron, P James, R Abdul‐Kadir, PA Kouides, ...
    Journal of Thrombosis and Haemostasis 19 (8), 1883-1887 2021
    Citations: 146

  • Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis
    J Servante, G Swallow, JG Thornton, B Myers, S Munireddy, ...
    BMC pregnancy and childbirth 21, 1-14 2021
    Citations: 142

  • Hemostatic laboratory derangements in COVID-19 with a focus on platelet count
    A Amgalan, M Othman
    Platelets 31 (6), 740-745 2020
    Citations: 139

  • Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease
    LA O'Brien, PD James, M Othman, E Berber, C Cameron, CRP Notley, ...
    Blood 102 (2), 549-557 2003
    Citations: 126

  • Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendations from the women's SSC of the ISTH
    A Amgalan, T Allen, M Othman, HK Ahmadzia
    Journal of Thrombosis and Haemostasis 18 (8), 1813-1838 2020
    Citations: 122

  • Exploring possible mechanisms for COVID‐19 induced thrombocytopenia: Unanswered questions
    A Amgalan, M Othman
    Journal of Thrombosis and Haemostasis 18 (6), 1514-1516 2020
    Citations: 113

  • Thromboelastography (teg)
    M Othman, H Kaur
    Hemostasis and thrombosis: methods and protocols, 533-543 2017
    Citations: 102

  • Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease
    M Othman, C Notley, FL Lavender, H White, CD Byrne, D Lillicrap, ...
    Blood 105 (11), 4330-4336 2005
    Citations: 100

  • DIC in pregnancy–pathophysiology, clinical characteristics, diagnostic scores, and treatments
    O Erez, M Othman, A Rabinovich, E Leron, F Gotsch, J Thachil
    Journal of blood medicine, 21-44 2022
    Citations: 99

  • Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer
    M Toukh, DR Siemens, A Black, S Robb, M Leveridge, CH Graham, ...
    Thrombosis research 133 (1), 88-95 2014
    Citations: 93

  • COVID‐19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women’s Health
    RA Kadir, T Kobayashi, T Iba, O Erez, J Thachil, S Kazi, AK Malinowski, ...
    Journal of Thrombosis and Haemostasis 18 (11), 3086-3098 2020
    Citations: 90

  • Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice
    M Qadura, B Waters, E Burnett, R Chegeni, S Bradshaw, C Hough, ...
    Blood, The Journal of the American Society of Hematology 114 (4), 871-880 2009
    Citations: 81

  • Frequency of platelet type versus type 2B von Willebrand disease
    A Hamilton, M Ozelo, J Leggo, C Notley, H Brown, JP Frontroth, ...
    Thrombosis and haemostasis 105 (03), 501-508 2011
    Citations: 75

  • Platelet-type von Willebrand disease: new insights into the molecular pathophysiology of a unique platelet defect
    M Othman, H Kaur, J Emsley
    Seminars in thrombosis and hemostasis 39 (06), 663-673 2013
    Citations: 66